Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence

Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence […]
COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients

For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And now, with the integration of AI into our data curation process, we have the potential to do data-assisted clinical research with more speed […]
Real-world data gets high marks for feasibility in lung cancer research: A cross-industry collaboration is advancing RWD

The real world is an unpredictable place. It can be messy and confusing, full of challenges and uncertainties that have to be overcome before we can move forward with confidence and clarity toward our goals. The same is true of the real-world data (RWD) generated by clinicians, health plans, medical devices, patients, and more. Before […]
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation

New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
Real-World Data Champion Robert Califf Nominated for FDA Commissioner

Dr. Califf is a staunch advocate for the use of real-world data (RWD) and real-world evidence (RWE) in the clinical trial ecosystem, with a long history of leveraging RWD and RWE to transform the life sciences community.
Roche is Validating the Utility of Real-World Evidence as a comparator to Single-arm Clinical Trials
A new study from Roche finds concerns around real-world evidence as a comparator to single-arm trials may be unfounded.